

Title: **Biologic Medications Within Dermatology**

Reference Number: RDF1215-23

Date of Response: 02/02/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Dear Northern Devon Healthcare NHS Trust,

I am analysing the usage of new biologic medications within dermatology. Could you please tell me how many patients were treated in November 2022 (or latest available month) by the dermatology department with the following drugs:

Drug	No. Patients treated
<i>Abrocitinib (Cibinqo)</i>	Nil
<i>Baricitinib (Olmiant)</i>	Nil
<i>Bimekizumab (Bimzelx)</i>	Nil
<i>Brodalumab (Kyntheum)</i>	≤5
<i>Dupilumab (Dupixent)</i>	Nil
<i>Ixekizumab (Taltz)</i>	≤5
<i>Risankizumab (Skyrizi)</i>	≤5
<i>Guselkumab (Tremfya)</i>	Nil
<i>Secukinumab (Cosentyx)</i>	≤5
<i>Tildrakizumab (Ilumetri)</i>	Nil
<i>Tralokinumab (Adtralza)</i>	Nil
<i>Upadacitinib (Rinvoq)</i>	Nil
<i>Ustekinumab (Stelara)</i>	Nil

Answer: Please note that Northern Devon Healthcare NHS Trust and the Royal Devon and Exeter NHS Foundation Trust merged on 1 April 2022 to become the Royal Devon University Healthcare NHS Foundation Trust.

As requested, information has been provided by the Royal Devon University Healthcare NHS Foundation Trust - Northern Services only (previously Northern Devon Healthcare NHS Trust).

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.